{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:28:01Z","timestamp":1793798881098,"version":"4.6.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR 305-Z02"],"award-info":[{"award-number":["TRR 305-Z02"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR 305-Z01"],"award-info":[{"award-number":["TRR 305-Z01"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["509149993\/TRR 374-INF"],"award-info":[{"award-number":["509149993\/TRR 374-INF"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["401821119\/GRK 2504-C5"],"award-info":[{"award-number":["401821119\/GRK 2504-C5"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","award":["Nr. 2024.022.1"],"award-info":[{"award-number":["Nr. 2024.022.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2023_EKES.07"],"award-info":[{"award-number":["2023_EKES.07"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2024_EKCS.08"],"award-info":[{"award-number":["2024_EKCS.08"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2020_EKEA.129"],"award-info":[{"award-number":["2020_EKEA.129"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","award":["YSF-TP01"],"award-info":[{"award-number":["YSF-TP01"]}],"id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["CA230411"],"award-info":[{"award-number":["CA230411"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70116726"],"award-info":[{"award-number":["70116726"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70116778"],"award-info":[{"award-number":["70116778"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70116777"],"award-info":[{"award-number":["70116777"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.euo.2026.07.001","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:15:55Z","timestamp":1788174955000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Landscape of Actionable Genetic Alterations in Advanced Urothelial Carcinoma: High Prevalence but Limited Clinical Use"],"prefix":"10.1016","author":[{"given":"Maria Giulia","family":"Carta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"T\u00f6gel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Angeloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Sieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Fiebig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Wach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helge","family":"Taubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Manseck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Meidenbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Spoerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Wullich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Haller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvia","family":"Ferrazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.07.001_b0005","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315\u201322.","DOI":"10.1038\/nature12965"},{"key":"10.1016\/j.euo.2026.07.001_b0010","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.euo.2026.07.001_b0015","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41585-023-00847-7","article-title":"Molecular profile of bladder cancer progression to clinically aggressive subtypes","volume":"21","author":"Guo","year":"2024","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2026.07.001_b0020","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.07.001_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111859","article-title":"Genomic heterogeneity as a barrier to precision oncology in urothelial cancer","volume":"41","author":"Clinton","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.euo.2026.07.001_b0030","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.07.001_b0035","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","article-title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.07.001_b0040","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.07.001_b0045","unstructured":"US Food and Drug Administration. 2025. FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-erdafitinib-locally-advanced-or-metastatic-urothelial-carcinoma."},{"key":"10.1016\/j.euo.2026.07.001_b0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.11181","article-title":"Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy","volume":"6","author":"Aggarwal","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2026.07.001_b0055","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010311","article-title":"Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types","volume":"13","author":"Gandara","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euo.2026.07.001_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the Phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.07.001_b0065","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.euf.2020.08.001","article-title":"Comprehensive genomic profiling of upper-tract and bladder urothelial carcinoma","volume":"7","author":"Necchi","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2026.07.001_b0070","article-title":"Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.euo.2026.07.001_b0075","article-title":"Comprehensive comparison of somatic, germline, and immune cell profiles in upper tract and bladder urothelial carcinoma","volume":"9","author":"Yuen","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.euo.2026.07.001_b0080","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1038\/s41467-022-33980-9","article-title":"Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer","volume":"13","author":"Damrauer","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2026.07.001_b0085","doi-asserted-by":"crossref","first-page":"148.e17","DOI":"10.1016\/j.urolonc.2022.12.008","article-title":"Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients","volume":"41","author":"Gerald","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2026.07.001_b0090","doi-asserted-by":"crossref","first-page":"8603","DOI":"10.1038\/s41467-024-52915-0","article-title":"The genomic and transcriptomic landscape of metastastic urothelial cancer","volume":"15","author":"Loriot","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2026.07.001_b0095","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.eururo.2022.01.026","article-title":"Comprehensive molecular characterization reveals genomic and transcriptomic subtypes of metastatic urothelial carcinoma","volume":"81","author":"Nakauma-Gonz\u00e1lez","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.07.001_b0100","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000162","article-title":"Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy","volume":"8","author":"Eckstein","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euo.2026.07.001_b0105","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1158\/2326-6066.CIR-18-0758","article-title":"The tumor immune microenvironment drives a prognostic relevance that correlates with bladder cancer subtypes","volume":"7","author":"Pfannstiel","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.euo.2026.07.001_b0110","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/his.15130","article-title":"Associations of TACSTD2\/TROP2 and NECTIN-4\/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts","volume":"84","author":"Bahlinger","year":"2024","journal-title":"Histopathology"},{"key":"10.1016\/j.euo.2026.07.001_b0115","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.07.001_b0120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000495251","article-title":"No evidence of microsatellite instability and loss of mismatch-repair-protein expression in squamous cell carcinoma of the penis","volume":"86","author":"Stoehr","year":"2019","journal-title":"Pathobiology"},{"key":"10.1016\/j.euo.2026.07.001_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2025.104191","article-title":"Robust consensus molecular subtyping of muscle-invasive bladder cancer via 3' RNA sequencing of formalin-fixed paraffin-embedded tissues: potential impact for clinical and trial settings","volume":"105","author":"Angeloni","year":"2025","journal-title":"Lab Invest"},{"key":"10.1016\/j.euo.2026.07.001_b0130","doi-asserted-by":"crossref","first-page":"10914","DOI":"10.1038\/s41467-024-55331-6","article-title":"AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer","volume":"15","author":"Bannier","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2026.07.001_b0135","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.3390\/cancers13102327","article-title":"Integration of spatial PD-L1 expression with the tumor immune microenvironment outperforms standard PD-L1 scoring in outcome prediction of urothelial cancer patients","volume":"13","author":"Weyerer","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euo.2026.07.001_b0140","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jmoldx.2026.03.004","article-title":"Oncogenicity variant interpreter (OncoVI) supports harmonized somatic variant interpretation in precision oncology","volume":"28","author":"Carta","year":"2026","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.euo.2026.07.001_b0145","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","article-title":"The Ensembl variant effect predictor","volume":"17","author":"McLaren","year":"2016","journal-title":"Genome Biol"},{"key":"10.1016\/j.euo.2026.07.001_b0150","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2021, https:\/\/www.R-project.org\/."},{"key":"10.1016\/j.euo.2026.07.001_b0155","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/gb-2004-5-10-r80","article-title":"Bioconductor: open software development for computational biology and bioinformatics","volume":"5","author":"Gentleman","year":"2004","journal-title":"Genome Biol"},{"key":"10.1016\/j.euo.2026.07.001_b0160","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.euo.2023.07.011","article-title":"Proposal for a novel histological scoring system as a potential grading approach for muscle-invasive urothelial bladder cancer correlating with disease aggressiveness and patient outcomes","volume":"7","author":"Eckstein","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.07.001_b0165","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41698-021-00204-0","article-title":"Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer","volume":"5","author":"Nakamura","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.euo.2026.07.001_b0170","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.07.001_b0175","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1158\/1078-0432.CCR-20-4548","article-title":"Phase II clinical trial of everolimus in a pan-cancer cohort of patients with mTOR pathway alterations","volume":"27","author":"Adib","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.07.001_b0180","article-title":"Epigenetics: mechanisms, potential roles, and therapeutic strategies in cancer progression","volume":"11","author":"Wang","year":"2024","journal-title":"Genes Dis"},{"key":"10.1016\/j.euo.2026.07.001_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100049","article-title":"Homologous recombination repair deficiency: an overview for pathologists","volume":"36","author":"Doig","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.euo.2026.07.001_b0190","article-title":"STAG2 regulates homologous recombination repair and sensitivity to ATM inhibition","volume":"10","author":"Zhou","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.euo.2026.07.001_b0195","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/ng.3692","article-title":"Clonal evolution of chemotherapy-resistant urothelial carcinoma","volume":"48","author":"Faltas","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.euo.2026.07.001_b0200","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.eururo.2022.10.020","article-title":"Spatial Immunephenotypes of distant metastases but not matched primary urothelial carcinomas predict response to immune checkpoint inhibition","volume":"83","author":"Erlmeier","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.07.001_b0205","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.07.001_b0210","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer","volume":"42","author":"Kl\u00fcmper","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.07.001_b0215","article-title":"Real-world outcomes of molecular tumor board treatment recommendations","volume":"9","author":"Nichetti","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.euo.2026.07.001_b0220","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s00432-022-04165-0","article-title":"Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board","volume":"149","author":"Heinrich","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.euo.2026.07.001_b0225","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/s41416-026-03422-0","article-title":"Implementing whole genome and transcriptome sequencing for cancer patients in routine healthcare: a comprehensive guide to costing","volume":"134","author":"Altb\u00fcrger","year":"2026","journal-title":"Br J Cancer"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:45:56Z","timestamp":1793796356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126001902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":45,"alternative-id":["S2588931126001902"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.07.001","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Landscape of Actionable Genetic Alterations in Advanced Urothelial Carcinoma: High Prevalence but Limited Clinical Use","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}